mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.
Relevant topics include (but are not be limited to):
Antibody engineering and selection
Targets relevant to cancer, immune-mediated disorders, and other diseases
Non-clinical studies of antibodies, e.g., mechanism of action studies, safety and efficacy studies in animals
Regulatory review of antibody therapeutics
Post-approval topics, e.g., pricing, reimbursement and markets
Emerging markets for antibody therapeutics, including China and India
All submitted manuscripts are subjected to initial evaluation by the editorial staff, and, if found suitable for further consideration, manuscripts are sent to peer review by independent, anonymous expert referees.